BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 18-Feb-2020

The Company has informed that the Board of Directors has taken the following decisions i) The Company shall establish a virtually wholly owned subsidiary Company in the name and style of "Square Lifesciences Ltd." in order to manufacture pharmaceuticals Oral Solid Dosage products. (cont.)

SQURPHARMA 29-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 4.18 for October-December 2019 as against Tk. 3.70 for October-December 2018; Consolidated EPS was Tk. 8.16 for July-December 2019 as against Tk. 7.46 for July-December 2018. Consolidated NOCFPS was Tk. 5.88 for July-December 2019 as against Tk. 6.83 for July-December 2018. Consolidated NAV per share was Tk. 84.12 as on December 31, 2019 and Tk. 80.40 as on June 30, 2019.

SQURPHARMA 23-Jan-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.

SQURPHARMA 21-Jan-2020

Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.

SQURPHARMA 21-Jan-2020

Mr. Anjan Chowdhury, one of the Directors of the Company, has expressed his intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.

SQURPHARMA 21-Jan-2020

The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2019 to the respective shareholders.

SQURPHARMA 16-Jan-2020

Tapan Chowdhury, one of the Directors of the Company, has expressed his intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.

SQURPHARMA 16-Jan-2020

Samuel S Chowdhury, one of the Directors of the Company, has expressed his intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.

SQURPHARMA 23-Dec-2019

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2019; unaudited financials up to September 30, 2019 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

SQURPHARMA 17-Dec-2019

The Company has informed that it has credited the Bonus shares for the year ended on June 30, 2019 to the respective shareholders' BO Accounts on December 17, 2019.

Previous Next page